RICHARD LAPAGE: Open Payments
NPI 1477005205 · CONCORD, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,237 in 62 payments from 11 companies in 2025. Trend: 2023 $991 · 2024 $1,044 · 2025 $1,237
Food & beverage: $1,237
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $292 |
| Gilead Sciences, Inc. | 15 | $271 |
| ABBVIE INC. | 9 | $197 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $173 |
| PFIZER INC. | 11 | $149 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
| Novo Nordisk Inc | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
Products named: AIRSUPRA, CAPLYTA, Yeztugo, QULIPTA, UBRELVY, NURTEC ODT, ELIQUIS, Kerendia.
Industry payments across NH — which companies pay providers there.
